RxDoctor Payments Data

Marlou Heiland, MD

Urology · Chandler, AZNPI 1730180431

Payments from drug & device makers

$774in general payments, 2019–2025

Across 39 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$222
  • Boston Scientific$150
  • 180 Medical, Inc.$86
  • Axonics, Inc.$62
  • AbbVie$49
  • Rochester Medical Corporation$36
  • plus $169 from 8 others

What the payments were for

  • Food & beverage$774100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc11$222
Boston Scientific7$150
180 Medical, Inc.5$86
Axonics, Inc.2$62
AbbVie(2 entities)3$49
Rochester Medical Corporation2$36
Isoray, Inc1$31
C. R. Bard, Inc. & Subsidiaries2$31
Sumitomo Pharma America, Inc.1$20
Teleflex LLC1$19
Calyxo, Inc.1$19
Neotract Inc.1$19
Coloplast1$16
Johnson & Johnson1$14

How this compares

$774 in reported general payments places this provider in the 25th percentile of 269 urology providers in Arizona.

See all urology providers in Arizona

Medicare billing

Part B allowed, 2024
$70,325
Medicare patients
338
Services billed
903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron127$112,667
GemtesaVibegron98$62,933
Tamsulosin Hcl243$4,356
Finasteride197$3,322
Solifenacin Succinate53$2,989
NitrofurantoinNitrofurantoin Macrocrystal32$1,553
Potassium Citrate ErPotassium Citrate11$1,090
Estradiol14$978
Alfuzosin Hcl ErAlfuzosin Hcl30$908
Oxybutynin Chloride ErOxybutynin Chloride25$827
Trospium Chloride17$815
Cephalexin69$525
Doxazosin Mesylate18$265
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$235
Ciprofloxacin Hcl36$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$222$112,667127 claims
Sumitomo Pharma America, Inc.Gemtesa$20$62,93398 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 269 urology providers in Arizona.

Other urology in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →